Full Press Release Details
CorMedix Notified of NYSE MKT Listing
Also Defers License Milestone Payment
Bridgewater, New Jersey, April 11, 2013
(Business Wire) - CorMedix Inc. ("CorMedix") (NYSE MKT: CRMD), a pharmaceutical company focused on developing
and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, received a notice from the NYSE
MKT on April 5, 2013 indicating that it is below listing standard criteria. In its Form 10-K for the fiscal year ended December
31, 2012. CorMedix reported stockholders' equity of less than $2 million and did not meet certain of the NYSE MKT continued
listing standards as set forth in the NYSE MKT Company Guide.
Under NYSE MKT regulations, CorMedix must
submit a plan of compliance no later than May 6, 2013 to address how it intends to regain compliance by October 20, 2013. If that
plan is accepted by NYSE MKT, CorMedix may be able to continue its listing during the 1003(a)(i) Plan Period, during which time
CorMedix will be subject to periodic review to determine whether it is making progress consistent with the plan.
CorMedix received notice on April 20, 2012
from the NYSE MKT informing it that CorMedix was below certain of the NYSE MKT's continued listing standards due to financial
impairment. CorMedix was afforded the opportunity to submit a plan to the NYSE MKT to regain compliance and, on May 17, 2012, presented
its plan to the NYSE MKT. On June 27, 2012, the NYSE MKT accepted CorMedix's plan and granted it an extension until August
22, 2012 to regain compliance with the continued listing standards. On September 21, 2012, the NYSE MKT notified CorMedix that
it granted CorMedix another extension to January 31, 2013 and on February 1, 2013, NYSE MKT notified that CorMedix was further
granted extension until April 15, 2013 to regain compliance with the continued listing standards of the NYSE MKT.
If CorMedix is not in compliance with all
of the NYSE MKT's continued listing standards within the timeframes provided, or does not make progress consistent with the
prior plan or the new plan to be submitted to the NYSE MKT during the respective plan period, the NYSE MKT will initiate delisting
"As we await the final review of
a CE Mark for our lead product Neutrolin , we are working diligently to address this deficiency and manage our cash
flow," said Randy Milby, CEO of CorMedix. "We anticipate compliance with the NYSE MKT listing standards from additional
financing we will seek after the anticipated receipt of the CE Mark. In addition, ND Partners, a large shareholder and part of
the Bollard Group, the grantors of our worldwide patent estate, has agreed to allow us to defer the major milestone payment due
upon receipt of the CE Mark for up to one year in order for us to prioritize resources for the planned launch of Neutrolin ."
CorMedix Inc. is a pharmaceutical company
that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac and renal
dysfunction, also known as cardiorenal disease. CorMedix most advanced product candidate is CRMD003 (Neutrolin )
for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central
venous catheters used for vascular access in hemodialysis patients. Please see www.cormedix.com for additional information.
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements
of historical facts, regarding management's expectations, beliefs, goals, plans or CorMedix's prospects, future financial position,
future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ
materially from projections or estimates due to a variety of important factors, including: CorMedix's ability to maintain its
listing on the NYSE MKT; obtaining regulatory approvals to conduct clinical trials and to commercialize CorMedix's product candidates,
including CE Marking for Neutrolin in Europe; the outcome of clinical trials of CorMedix's product candidates
and whether they demonstrate these candidates' safety and effectiveness; the risks and uncertainties associated with CorMedix's
ability to manage its limited cash resources, obtaining additional financing to support CorMedix's research and development and
clinical activities and operations; CorMedix's ability to enter into and maintain collaborations with third parties for its development
programs; CorMedix's dependence on its collaborations and its license relationships; achieving milestones under CorMedix's collaborations;
CorMedix's dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers
and consultants; and protecting the intellectual property developed by or licensed to CorMedix. These and other risks are described
in greater detail in CorMedix's filings with the SEC, copies of which are available free of charge at the SEC's website
at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking
statements, and investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend
to update these forward-looking statements, except as required by law.
Chief Executive Officer